| Recruiting | Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Re NCT07166419 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Recruiting | CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphobl NCT06777979 | St. Jude Children's Research Hospital | Phase 1 |
| Recruiting | Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Po NCT06447987 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leuke NCT05761171 | Children's Oncology Group | Phase 2 |
| Recruiting | Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lym NCT05418088 | Sumithira Vasu | Phase 1 |
| Terminated | Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia NCT04526795 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acu NCT04752163 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer NCT03739606 | City of Hope Medical Center | Phase 2 |
| Terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524 | OHSU Knight Cancer Institute | Phase 1 |
| Withdrawn | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem C NCT03807063 | Fred Hutchinson Cancer Center | Phase 1 |
| Active Not Recruiting | Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leuke NCT03512405 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Recruiting | 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Ris NCT03670966 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Rela NCT03576547 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acu NCT03519984 | University of Southern California | Phase 1 |
| Recruiting | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After NCT03326921 | Fred Hutchinson Cancer Center | Phase 1 |
| Active Not Recruiting | Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Posit NCT03147612 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leuke NCT03094611 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positi NCT03263572 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, A NCT03128034 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lympho NCT03136146 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leuk NCT03132454 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia NCT02767934 | University of Washington | Phase 2 |
| Active Not Recruiting | Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer U NCT02861417 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies NCT02706392 | Fred Hutchinson Cancer Center | Phase 1 |
| Recruiting | ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome NCT02392572 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory NCT02551718 | University of Washington | N/A |
| Active Not Recruiting | Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patient NCT02143414 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Rela NCT02220985 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagno NCT02199184 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia NCT02146924 | City of Hope Medical Center | Phase 1 |
| Completed | Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in R NCT02083250 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Tran NCT01822509 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | NK Cells in Cord Blood Transplantation NCT01619761 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelog NCT01620216 | OHSU Knight Cancer Institute | Phase 2 |
| Completed | Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive NCT00390793 | M.D. Anderson Cancer Center | Phase 2 |